ArriVent BioPharma Stock Forecast

Stock Price Forecast

According to 12 analysts polled by S&P Global, ArriVent BioPharma stock has a consensus rating of "Strong Buy" and an average price target of $42.1. The average 1-year stock price forecast is 38.03% higher than the current stock price, while the lowest is $25.25 (-17.21%) and the highest is $50 (+63.93%).

Price Target: $42.1 (+38.03%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$25.25	$42.1	$44.5	$50
Change	-17.21%	+38.03%	+45.90%	+63.93%

Analyst Ratings

The average analyst rating for ArriVent BioPharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	12	12	11	12	12	12
Buy	0	0	0	0	0	0
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	12	12	11	12	12	12

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Asthika Goonewardene Truist Financial	Truist Financial	Buy Initiates $43 → $45	Buy	Initiates	$43 → $45	+47.54%	May 29, 2026
Mayank Mamtani B. Riley Securities	B. Riley Securities	Buy Maintains $45	Buy	Maintains	$45	+47.54%	May 19, 2026
Sam Slutsky LifeSci Capital	LifeSci Capital	Buy Maintains $42	Buy	Maintains	$42	+37.70%	May 17, 2026
Yigal Nochomovitz Citi	Citi	Buy Reiterates $45 → $43	Buy	Reiterates	$45 → $43	+40.98%	May 13, 2026
Jeff Jones Oppenheimer	Oppenheimer	Buy Reiterates $50	Buy	Reiterates	$50	+63.93%	May 12, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

42.41M

EPS This Year

-4.06

from -4.32

EPS Next Year

-3.48

from -4.06

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	-	-
Operating Income	-11.59M	-36.91M	-74.59M	-94.31M	-177.53M	-200.54M
Net Income	-68.81M	-36.91M	-69.33M	-80.49M	-166.31M	-194.12M
EPS	-	-	-	-	-4.32	-4.06
Free Cash Flow	-	-29.81M	-32.80M	-48.64M	-101.58M	-168.99M
No. Analysts	-	-	-	-	-	10

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Revenue Growth	2027	2028
High	-
Avg	-
Low	-

EPS Forecast

EPS	2026	2027	2028
High	-3.32
Avg	-4.06
Low	-4.62

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-